Jilin Aodong Pharmaceutical Group Co Ltd (000623) — Cash Flow-to-Debt Ratio
Jilin Aodong Pharmaceutical Group Co Ltd (000623) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥112.12 Million could theoretically repay 0% of its total liabilities (CN¥3.76 Billion) in one year. See 000623 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jilin Aodong Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Jilin Aodong Pharmaceutical Group Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see 000623 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Jilin Aodong Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Jilin Aodong Pharmaceutical Group Co Ltd. Check earnings quality score of Jilin Aodong Pharmaceutical Group Co Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥272.26 Million | CN¥3.53 Billion | ▲ +382.2% |
| 2024 | 0.02x | CN¥59.48 Million | CN¥3.72 Billion | ▲ +12.0% |
| 2023 | 0.01x | CN¥68.06 Million | CN¥4.77 Billion | ▼ -83.7% |
| 2022 | 0.09x | CN¥423.86 Million | CN¥4.84 Billion | ▲ +8.5% |
| 2021 | 0.08x | CN¥324.85 Million | CN¥4.03 Billion | ▼ -19.9% |
| 2020 | 0.10x | CN¥390.41 Million | CN¥3.88 Billion | ▼ -10.9% |
| 2019 | 0.11x | CN¥379.46 Million | CN¥3.36 Billion | ▲ +11.0% |
| 2018 | 0.10x | CN¥347.64 Million | CN¥3.41 Billion | ▼ -47.7% |
| 2017 | 0.19x | CN¥256.49 Million | CN¥1.32 Billion | ▼ -14.5% |
| 2016 | 0.23x | CN¥333.81 Million | CN¥1.47 Billion | ▲ +32.0% |
| 2015 | 0.17x | CN¥388.03 Million | CN¥2.25 Billion | ▼ -33.7% |
| 2014 | 0.26x | CN¥288.83 Million | CN¥1.11 Billion | ▲ +30.0% |
| 2013 | 0.20x | CN¥201.22 Million | CN¥1.01 Billion | ▼ -11.3% |
| 2012 | 0.23x | CN¥272.40 Million | CN¥1.21 Billion | ▲ +105.3% |
| 2011 | 0.11x | CN¥108.30 Million | CN¥985.86 Million | ▼ -58.9% |
| 2010 | 0.27x | CN¥174.22 Million | CN¥652.43 Million | ▼ -24.6% |
| 2009 | 0.35x | CN¥213.03 Million | CN¥601.83 Million | ▼ -4.4% |
| 2008 | 0.37x | CN¥235.03 Million | CN¥634.74 Million | ▼ -28.3% |
| 2007 | 0.52x | CN¥384.69 Million | CN¥744.94 Million | ▲ +159.4% |
| 2006 | 0.20x | CN¥187.99 Million | CN¥944.28 Million | ▲ +21.3% |
| 2005 | 0.16x | CN¥136.26 Million | CN¥829.84 Million | ▼ -33.1% |
| 2004 | 0.25x | CN¥218.53 Million | CN¥890.13 Million | ▼ -0.2% |
| 2003 | 0.25x | CN¥147.65 Million | CN¥600.19 Million | ▲ +3379.2% |
| 2002 | -0.01x | CN¥-4.58 Million | CN¥609.94 Million | ▼ -102.8% |
| 2001 | 0.27x | CN¥138.76 Million | CN¥512.58 Million | ▲ +14.3% |
| 2000 | 0.24x | CN¥77.04 Million | CN¥325.23 Million | ▼ -0.1% |
| 1999 | 0.24x | CN¥110.18 Million | CN¥464.78 Million | ▲ +263.0% |
| 1998 | -0.15x | CN¥-30.90 Million | CN¥212.43 Million | — |